NHS approves AbbVie's Elahere

The United Kingdom — National Health Service>>> in the United Kingdom>>> has approved Mirvetuximab soravtansine (mirvetuximab soravtansine), a new targeted therapy for women with platinum-resistant ovarian, fallopian tube, or peritoneal cancers. This marks the first new treatment for this hard-to-treat disease in two decades. Developed by AbbVie>>>, Mirvetuximab soravtansine works as an antibody-drug conjugate, targeting cancer cells with a specific protein (folate receptor alpha) and delivering a cancer-killing molecule. Clinical trials, including those involving eight United Kingdom — National Health Service>>> hospitals, demonstrated that the drug improved patient survival by an average of four months and reduced tumor size in a higher percentage of patients compared to traditional chemotherapy, with more tolerable side effects. The United Kingdom — National Institute for Health and Care Research>>> recommended its use, and it is estimated that up to 400 women in England could benefit annually. Charities like Ovacome>>> and Ovarian cancer have lauded the decision as a landmark moment, offering renewed hope and improved quality of life for patients who previously had limited treatment options.